NERV — Minerva Neurosciences, Inc.

Summary of Minerva Neurosciences Q1 2023 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of March 31, 2023, cash, cash equivalents, and restricted cash totaled approximately $36.1 million, slightly down from $36.2 million at the end of 2022.
• Net Loss: The company reported a net loss of approximately $7 million for Q1 2023, translating to a net loss per share of $1.31, an improvement from a net loss of approximately $9.8 million or $1.83 per share in Q1 2022.
• Research and Development (R&D) Expenses: R&D expenses decreased to $2.7 million from $5 million year-over-year, primarily due to lower non-cash stock compensation and consultant fees.
• General and Administrative (G&A) Expenses: G&A expenses also decreased to $2.7 million from $3 million, attributed to reduced non-cash stock compensation costs.

2. Strategic Updates and Business Highlights

• Roluoperidone NDA: The FDA confirmed the filing of Minerva's New Drug Application (NDA) for roluperidone on April 27, 2023, with a standard review timeline and a PDUFA goal date of February 26, 2024. The FDA does not plan to hold an advisory committee for this review.
• Unique Treatment Approach: Roluoperidone targets negative symptoms of schizophrenia, a significant unmet need in the market, as there are currently no approved treatments for these symptoms in the U.S.
• Clinical Trial Results: The Phase 2b study met its primary endpoint, while the Phase 3 study showed nominal statistical significance for the 64 mg dose. The company emphasized the potential for roluperidone to improve daily functioning in patients.

3. Forward Guidance and Outlook

• The company expects its existing cash resources to be sufficient to meet capital requirements for at least the next 12 months.
• Minerva is considering potential partnerships for the launch of roluperidone, indicating that they are evaluating their needs for commercialization as they approach the potential approval date.

4. Bad News, Challenges, or Points of Concern

• FDA Review Issues: The FDA has previously raised concerns regarding the conduct of clinical trials and the potential use of roluperidone in patients already on antipsychotics. Although the NDA was filed, ongoing dialogue with the FDA is necessary to address any remaining questions.
• Statistical Significance: The Phase 3 study did not achieve the required statistical significance for the 32 mg dose, which may raise concerns about the robustness of the data.
• Market Competition: The company faces competition from other treatments for schizophrenia, particularly those that may indirectly address negative symptoms.

5. Notable Q&A Insights

• FDA Engagement: Management highlighted that the recent engagement with the FDA, including a face-to-face meeting, was crucial in getting the NDA filed and emphasized that no new data were added, but rather a re-explanation of existing data.
• Launch Strategy: The company is contemplating whether to market roluperidone independently or seek a partner, with a focus on ensuring readiness for a potential launch in 2024.
• Remaining Economics from Seltorexant: Minerva has approximately $95 million in remaining milestone payments from their agreement with Royalty Pharma, including $10 million tied to Phase 3 study outcomes and $60 million related to regulatory approvals.

Overall, Minerva Neurosciences is positioned for a pivotal year with the potential approval of roluperidone, although it faces challenges in the FDA review process and market competition.